Drug details

Tepmetko (tepotinib tablets)

type of MET Tyrosine Kinase Inhibitors

Tepmetko (tepotinib) is a kinase inhibitor used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

This drug may have the following side effects:

• nausea,
• vomiting,
• diarrhea,
• shortness of breath,
• constipation,
• musculoskeletal pain,
• fatigue,
• cough,
• abdominal pain,
• pneumonia,
• decreased lymphocytes,
• fluid retention (edema),
• decreased hemoglobin
• increased ALT,
• decreased albumin,
• fluid buildup around the lungs,
• decreased sodium,
• increased gamma-glutamyltransferase,
• increased amylase,
• increased AST, and

The following drugs are related to Tepmetko, either as a replacement or used together:

• Afinitor (everolimus tablets)
• Afinitor Disperz (everolimus tablets)
• Alecensa (alectinib capsules)
• Alimta (pemetrexed)
• Alunbrig (brigatinib tablets)
• Tecentriq (atezolizumab injection)
• Zirabev (bevacizumab-bvzr injection)
• Tabrecta (capmatinib tablets)
• Zykadia (ceritinib hard-gelatin capsules)
• Xalkori (crizotinib)
• Cyramza (ramucirumab solution for intravenous infusion)
• Tafinlar (dabrafenib capsules)
• Vizimpro (dacomitinib)
• Taxotere (docetaxel for injection)
• Imfinzi (durvalumab injection)
• Tarceva (erlotinib)
• Gavreto (pralsetinib capsules)
• Iressa (gefitinib)
• Gemzar (gemcitabine hcl)
• Infugem (gemcitabine in sodium chloride injection)
• Yervoy (ipilimumab injection)
• Keytruda (pembrolizumab for injection)
• Lorbrena (lorlatinib tablets)
• Lumakras (sotorasib tablets)
• Tagrisso (osimertinib tablets)